11/26
06:43 am
eypt
Eyepoint Pharmaceuticals (NASDAQ:EYPT) was upgraded by analysts at Cantor Fitzgerald to a "strong-buy" rating.
Low
Report
Eyepoint Pharmaceuticals (NASDAQ:EYPT) was upgraded by analysts at Cantor Fitzgerald to a "strong-buy" rating.
11/19
07:43 pm
eypt
EyePoint Pharmaceuticals (EYPT): Valuation Update Following Positive Phase 3 DURAVYU Safety Review [Yahoo! Finance]
Low
Report
EyePoint Pharmaceuticals (EYPT): Valuation Update Following Positive Phase 3 DURAVYU Safety Review [Yahoo! Finance]
11/19
07:13 am
eypt
EyePoint Announces Positive Recommendation from Independent Data Safety Monitoring Committee for Pivotal Phase 3 Trials for DURAVYU™ in Wet Age-Related Macular Degeneration [Yahoo! Finance]
Low
Report
EyePoint Announces Positive Recommendation from Independent Data Safety Monitoring Committee for Pivotal Phase 3 Trials for DURAVYU™ in Wet Age-Related Macular Degeneration [Yahoo! Finance]
11/19
07:00 am
eypt
EyePoint Announces Positive Recommendation from Independent Data Safety Monitoring Committee for Pivotal Phase 3 Trials for DURAVYU™ in Wet Age-Related Macular Degeneration
Medium
Report
EyePoint Announces Positive Recommendation from Independent Data Safety Monitoring Committee for Pivotal Phase 3 Trials for DURAVYU™ in Wet Age-Related Macular Degeneration
11/17
07:00 am
eypt
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
High
Report
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
11/9
07:23 am
eypt
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report [Yahoo! Finance]
Low
Report
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report [Yahoo! Finance]
11/7
04:20 am
eypt
EyePoint Pharmaceuticals Inc (EYPT) Q3 2025 Earnings Call Highlights: Strategic Advances Amid ... [Yahoo! Finance]
Medium
Report
EyePoint Pharmaceuticals Inc (EYPT) Q3 2025 Earnings Call Highlights: Strategic Advances Amid ... [Yahoo! Finance]
11/6
11:11 am
eypt
Eyepoint Pharmaceuticals (NASDAQ:EYPT) had its price target raised by analysts at Royal Bank Of Canada from $28.00 to $39.00. They now have an "outperform" rating on the stock.
Medium
Report
Eyepoint Pharmaceuticals (NASDAQ:EYPT) had its price target raised by analysts at Royal Bank Of Canada from $28.00 to $39.00. They now have an "outperform" rating on the stock.
11/5
07:00 am
eypt
EyePoint Reports Third Quarter 2025 Financial Results and Highlights Recent Corporate Developments
High
Report
EyePoint Reports Third Quarter 2025 Financial Results and Highlights Recent Corporate Developments
11/3
07:00 am
eypt
EyePoint Announces Participation at Upcoming Investor Conferences
Medium
Report
EyePoint Announces Participation at Upcoming Investor Conferences
10/29
07:00 am
eypt
EyePoint to Report Third Quarter 2025 Financial Results on November 5, 2025
Medium
Report
EyePoint to Report Third Quarter 2025 Financial Results on November 5, 2025
10/20
08:45 am
eypt
Eyepoint Pharmaceuticals (NASDAQ:EYPT) was given a new $28.00 price target on by analysts at Mizuho.
Low
Report
Eyepoint Pharmaceuticals (NASDAQ:EYPT) was given a new $28.00 price target on by analysts at Mizuho.
10/16
07:00 am
eypt
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Low
Report
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
10/14
10:43 pm
eypt
EyePoint Announces Pricing of Public Offering
Medium
Report
EyePoint Announces Pricing of Public Offering
10/14
04:51 pm
eypt
EyePoint Announces Pivotal Phase 3 Program Initiation for DURAVYU™ in Diabetic Macular Edema [Yahoo! Finance]
Medium
Report
EyePoint Announces Pivotal Phase 3 Program Initiation for DURAVYU™ in Diabetic Macular Edema [Yahoo! Finance]
10/14
04:35 pm
eypt
EyePoint Announces Proposed Public Offering of Common Stock
Medium
Report
EyePoint Announces Proposed Public Offering of Common Stock
10/14
04:30 pm
eypt
EyePoint files automatic mixed securities shelf [Seeking Alpha]
Medium
Report
EyePoint files automatic mixed securities shelf [Seeking Alpha]
10/14
04:01 pm
eypt
EyePoint Announces Pivotal Phase 3 Program Initiation for DURAVYU™ in Diabetic Macular Edema
High
Report
EyePoint Announces Pivotal Phase 3 Program Initiation for DURAVYU™ in Diabetic Macular Edema
9/16
07:00 am
eypt
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Medium
Report
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)